DENTSPLY SIRONA (XRAY) has opened 2026 with Q1 revenue of US$880 million and a basic EPS loss of US$0.05, alongside net income excluding extra items of a US$10 million loss, setting a cautious tone around current profitability. Over the past year, the company has seen quarterly revenue move between US$879 million and US$961 million, while basic EPS has ranged from a profit of US$0.10 to a loss of US$2.16. This underlines how volatile earnings have been even as the top line has stayed close to the US$900 million mark. For investors, the latest quarter keeps the spotlight firmly on margins and how quickly they can be rebuilt from these loss-making levels.

See our full analysis for DENTSPLY SIRONA.

With the headline numbers in place, the next step is to test them against the stories investors commonly tell about DENTSPLY SIRONA and see which narratives still fit and which start to look stretched.

Losses Narrow Versus 2025 Run Rate

• Q1 2026 shows a net income loss of US$10 million and basic EPS of US$0.05 loss, compared with trailing 12 month losses of US$628 million and basic EPS of US$3.15 loss, so the latest quarter sits against a much heavier recent run rate.
• Bulls argue that planned margin improvement could move the business from a US$628 million trailing loss toward positive earnings, and this quarter’s smaller loss sits alongside that story, but:
  • Trailing basic EPS of US$3.15 loss and five year annualised loss growth of about 40.4% show the business is still carrying a heavy profitability burden into any recovery case.
  • Forecast earnings growth of 76.92% per year, if achieved, would need to overcome that loss history before translating into the higher margins bulls are counting on.

Analysts who lean bullish point to a big swing in earnings over time, so it is worth stress testing that view against how the P&L is actually trending today. 🐂 DENTSPLY SIRONA Bull Case

Low P/S Multiple Versus DCF Fair Value

• With a P/S of 0.6x against a US Medical Equipment industry average of 2.7x and peer average of about 4x, and a DCF fair value of US$31.45 versus a current share price of US$11.14, the stock is priced well below both sector benchmarks and this model estimate.
• Bears highlight that this discount sits alongside slow expected revenue growth of 1.2% per year and ongoing losses, which may justify a low multiple, because:
  • Revenue on a trailing 12 month basis is US$3.7b with only modest growth expected, while margins are currently negative, so the business is not yet generating earnings to match the DCF fair value level.
  • The dividend yield of 5.75% is not covered by earnings or free cash flow, which supports the cautious view that cash generation, not just headline valuation gaps, matters for how the market prices the stock.

Skeptics often focus less on the size of the discount and more on whether the underlying business and cash flows support closing it over time. 🐻 DENTSPLY SIRONA Bear Case

Dividend Yield Sits Against Multi Year Losses

• The stock offers a 5.75% dividend yield, yet the business reported a US$628 million trailing 12 month net income loss and has seen losses grow at about 40.4% per year over the past five years, so payouts are being made alongside extended unprofitability.
• Consensus narrative sees long term dental care trends and digital platforms as potential supports for both earnings and cash flow, but the current numbers create a clear tension between income and resilience, because:
  • Revenue of US$3.7b on a trailing basis provides scale, yet negative margins mean those sales are not translating into earnings that can naturally fund a 5.75% yield.
  • Analysts expect revenue to grow at 1.2% per year, slower than the cited 11.3% for the broader US market, so any improvement in dividend coverage is likely to rely more on margin repair than on fast top line expansion.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for DENTSPLY SIRONA on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seen enough to get a feel for the mixed picture here? Use the full dataset, review the positives and negatives in detail, and weigh up the 3 key rewards and 1 important warning sign

Explore Alternatives

DENTSPLY SIRONA combines ongoing losses, uncovered dividends and a low P/S multiple with slow expected revenue growth. This combination keeps questions around resilience and risk firmly on the table.

If that mix of weak earnings and dividend strain makes you cautious, it is worth urgently checking out 74 resilient stocks with low risk scores so you can focus on companies with steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.